34 filings
Page 2 of 2
8-K
3ddn3p
16 Jun 21
Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths
4:29pm
8-K
kn8qxz gc28gnxa
2 Jun 21
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
6mtfbsf3jrwex5c7c28y
11 May 21
Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results
4:05pm
8-K
gr9oy9 zmqtgy
25 Mar 21
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
5:02pm
8-K
o08efk8xxo8e1c
1 Mar 21
Satsuma Pharmaceuticals Announces Updated STS101 Development Plan
12:00am
8-K
gonszedezh
10 Nov 20
Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
4:21pm
8-K
7t488n9hf7kgo
10 Sep 20
Other Events
4:40pm
8-K
9ti1mi15dmxni
11 Aug 20
Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
4:10pm
8-K
xav37853uga1qdt7bmt
7 Jul 20
Departure of Directors or Certain Officers
4:12pm
8-K
rn91ms1
15 Jun 20
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
hxhu9cdree99lkei
12 May 20
Satsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business Results
4:30pm
8-K
cdr8l w1sw
10 Mar 20
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Results
4:10pm
8-K
votqaoy 61tla
12 Nov 19
Satsuma Pharmaceuticals Reports Third Quarter 2019 Financial and Business Results
4:16pm
8-K
ib7r6n6t7
17 Sep 19
Satsuma Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
4:11pm